Meet Samuel – Your Personal Investing Prophet
- Start a conversation with TipRanks’ trusted, data-backed investment intelligence
- Ask Samuel about stocks, your portfolio, or the market and get instant, personalized insights in seconds
The latest update is out from Imunon ( (IMNN) ).
On February 2, 2026, Imunon, Inc. announced that Executive Vice President and Chief Scientific Officer Khursheed Anwer intends to retire, with his employment ending on February 20, 2026, and the company noted his departure does not stem from any disagreement with management. To ensure continuity, Imunon has entered into a retirement and consulting agreement under which Dr. Anwer will serve as a consultant through December 31, 2026 on a $10,000 monthly retainer and will receive a year of salary-based severance, COBRA coverage and standard accrued compensation, signaling an orderly leadership transition in its scientific ranks rather than a disruptive change.
The most recent analyst rating on (IMNN) stock is a Hold with a $3.00 price target. To see the full list of analyst forecasts on Imunon stock, see the IMNN Stock Forecast page.
Spark’s Take on IMNN Stock
According to Spark, TipRanks’ AI Analyst, IMNN is a Neutral.
The score is primarily constrained by weak financial performance (no revenue, sustained losses, and negative free cash flow) and a longer-term downtrend in technicals. Offsetting factors include constructive earnings-call updates (Phase III progress, regulatory milestone, and lower operating expenses), but near-term liquidity constraints and reliance on external capital remain key risks.
To see Spark’s full report on IMNN stock, click here.
More about Imunon
Average Trading Volume: 52,137
Technical Sentiment Signal: Sell
Current Market Cap: $10.61M
For detailed information about IMNN stock, go to TipRanks’ Stock Analysis page.